B. Riley Securities Reiterates Buy Rating on Unicycive Therapeutics
B. Riley Securities maintains its buy rating on Unicycive Therapeutics, Inc. with a $22 target price, a 356.55% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating on Unicycive Therapeutics, Inc., setting a price target of $22.
- B. Riley Securities's $22 price target implies 356.55% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.82 share price.
- Shares of NasdaqCM:UNCY traded at $4.59 on Wednesday, with a market cap of approximately $128.5 million.
- Insider buying was reported on May 14, 2026, with several executives acquiring shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities has reiterated its buy rating on Unicycive Therapeutics, Inc. (NasdaqCM: UNC), maintaining a price target of $22. This update from analyst Mayank Mamtani was issued on June 30, 2026.
B. Riley Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Unicycive Therapeutics
Millennium Management LLC increased its holdings by 384,505 shares, bringing its total to 1,399,348 shares, valued at approximately $9.2 million. Vanguard Capital Management LLC opened a new position with 811,430 shares worth about $5.3 million. Other funds like Vivo Capital, LLC and Octagon Capital Advisors LP kept their positions unchanged.
Unicycive Therapeutics, Inc. Stock Down 8.5%
Shares of NasdaqCM:UNCY traded near $4.59 on Wednesday. Unicycive Therapeutics, Inc. has a market cap of approximately $128.5 million and a forward P/E ratio of 0.86. The stock has experienced a 52-week low of $3.71 and a high of $8.74. It has a 50-day moving average of $7.56 and a 200-day moving average of $6.25. The company's current ratio stands at 2.40, with a quick ratio of 2.06 and a debt-to-equity ratio of 2.16.
$UNCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several executives at Unicycive Therapeutics, including EVP Pharmaceuticals and BD Pramod Gupta, EVP Corporate Strategy Douglas Jermasek, and CFO John Townsend, acquired 169,500 shares each. CEO Shalabh Gupta purchased 762,200 shares. All these transactions were not part of a 10b5-1 plan.
Analysts Set New Price Targets
On June 30, 2026, HC Wainwright & Co. also maintained a buy rating with a $15 target. Benchmark and Guggenheim have previously maintained buy ratings with targets of $18 and $37, respectively. The consensus among analysts is a strong buy, with a mean target price of $41.3.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company based in Mountain View, California. It focuses on developing therapies for kidney diseases. The company is working on oxylanthanum carbonate, a phosphate-binding agent for chronic kidney disease patients on dialysis, and UNI-494, aimed at treating acute kidney injury. Led by CEO Dr. Pramod Gupta, the company employs 21 people.
Bottom Line
B. Riley Securities' reiteration of its buy rating with a $22 target highlights ongoing confidence in Unicycive Therapeutics, Inc.'s potential. Investors often track such analyst updates for insights into stock valuation. Remember, these analyst ratings are backward-looking and may not reflect the current market conditions.
Get Unicycive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UNCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.